Keywords: Shire, Dermagraft, Canada approval, Patent settlement, Intuniv, ADHA, Anchen Pharma, TWi Pharma, USA
Shire's Dermagraft cleared in Canada; settles Intuniv litigation
Article | 06 September 2012
Ireland headquartered Shire (LSE: SHP), NASDAQ: SHPG) says that its lead regenerative medicine product, Dermagraft (human fibroblast-derived dermal substitute) has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
